We will present our preclinical work in #vascularmalformations at #VAC2025 today. As we advance our commitment to innovation, we’re preparing to initiate the Phase 1 clinical trial of RLY-2608 in PI3Kα-driven vascular malformations by the end of Q1. Congratulations Fabien & team!

Today, we celebrate nine years of innovation, dedication & impact. A huge thank you to our incredible team of Relayers and the patients, families & investigators who inspire our mission every day. Here’s to the past, the future, and the lives we strive to change - cheers to 9! 🎂

CEO @SanjivKPatel1 looks forward to presenting at #JPM25 as we continue to transform the #drugdiscovery landscape. Details below. We look forward to connecting in San Francisco!

𝘛𝘪𝘥𝘪𝘯𝘨𝘴 𝘰𝘧 𝘤𝘰𝘮𝘧𝘰𝘳𝘵 𝘢𝘯𝘥 𝘫𝘰𝘺 🎁 This holiday season, we partnered with @Thehopefactory to assemble bundles for children at local Boston-area hospitals. Each bundle included games related to STEM & the arts, and hopefully lots of 𝘤𝘰𝘮𝘧𝘰𝘳𝘵 𝘢𝘯𝘥 𝘫𝘰𝘺.

Today, we announced updated data for RLY-2608 + fulvestrant that continue to demonstrate clinically meaningful progression free survival. We look forward to presenting these data at #SABCS24 today. Find details & register for our 7AM ET conference call:

We are pleased to announce we will present updated clinical data for RLY-2608 + fulvestrant in patients with PI3Kα-mutated, HR+, HER2- locally advanced or metastatic #breastcancer at #SABCS24. More details here.

We’re pleased to announce we have entered into an exclusive global licensing agreement with @ElevarThera for lirafugratinib, a highly selective irreversible small-molecule inhibitor of FGFR2, in FGFR2-driven cholangiocarcinoma & other solid tumors.

At Relay Tx, we always gather for lunch. You grab a seat at any table with any colleague from any group. 🦃 Yesterday’s Thanksgiving lunch looked like any other day of the week - with extra gratitude and extra gravy.

Takeaways from our lunch with board member Jami Rubin: ✨Seek out your mentors; they won’t find you ✨Professional confidence takes time: put in the hours & reps ✨Operate from a place of fearlessness Thanks to Imogen Pryce & our ERG, EmpowHER, for organizing an inspiring chat!

It's #BreastCancerAwarenessMonth. Between 20-30% of women initially diagnosed w/ early-stage breast cancer will ultimately develop metastatic breast cancer. At Relay Tx, we are dedicated to advancing our mission of discovering & developing new medicines to help patients in need.

Earlier this month, we announced positive interim data for RLY-2608 in HR+/HER2- #BreastCancer. With a 9.2-month median progression free survival and 33% ORR, RLY-2608 has the potential to offer a level of benefit to patients that has not previously been possible with existing non-selective medicines. We are moving quickly to begin a pivotal study in 2025.

Today, we announced positive interim data for RLY-2608 demonstrating clinically meaningful progression free survival for RLY-2608 in patients with HR+/HER2- #BreastCancer. President of R&D Dr. Don Bergstrom shares more about the significance of these data below. Tune into our conference call this morning, September 9, at 8:00AM ET for details. $RLAY

We look forward to reporting new RLY-2608 data this Monday, September 9, and will discuss them on a webcast at 8:00AM ET. Full details: $RLAY

AI in drug discovery is leading precision medicine innovation. By integrating industry-leading tools in our Dynamo® platform, we have the potential to create novel medicines that were not previously possible to provide improved treatment options for patients. Check out @cbssaturday's feature on #AI in medicine, featuring Relay Tx President of R&D, Dr. Don Bergstrom.

We volunteered with local nonprofit @communityserv again this summer. Community Servings serves medically tailored, nutritious, made-from-scratch meals to chronically and critically ill individuals and their families across New England. #FoodHeals

Come as you are at Relay Tx. Thanks to our Relay Resource Group, PaRTi, we celebrated #Pride this month with our favorite traditions: Pride trivia, drag bingo and our @BAGLYinc fundraiser. 🌈

Just published! We're excited to share our 2023 Corporate Responsibility report, which highlights our efforts to operate sustainably and responsibly. This year's report includes updates on our commitment to our patients, people, environment, community and governance. Check it out on our website.

#ICYMI: Last week, we disclosed 3 new pre-clinical pipeline programs in #geneticdisease and solid tumors. For full details on these programs and how the Dynamo™ platform led to these discoveries, access the webcast recording here. $RLAY

(9/9) We are integrating industry-leading tools into our Dynamo™ platform to continue rapidly growing and evolving. This morning’s New Program & Platform event underscored the potential for our pipeline programs to help many patients in need. Learn more about the new programs we announced earlier today: $RLAY